LATEST NEWS | 5th Jul 2020 Anteris Technologies delivering on its goals despite pandemic

15th Jun 2020

ShareCafe's Hidden Gems Webinar – Anteris (AVR)

4th Jun 2020

StockPal Interview with Wayne Paterson

21st May 2020

Investor Presentation

30th Mar 2020

Investor Q&A with Dr. Paul Sorajja & our CEO

Latest News

Anteris Technologies delivering on its goals despite pandemic

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are underway and says he's extremely thrilled with the results to date from its first-in-human study. Paterson's expecting the company will end the year achieving all milestones set for 2020.

5th Jul 2020

ShareCafe's Hidden Gems Webinar – Anteris (AVR)

Latest video outlining Anteris direction to build the World's Most Durable Heart Valve

15th Jun 2020

StockPal Interview with Wayne Paterson

Anteris Technologies (ASX:AVR) – Wayne Paterson

4th Jun 2020

Bioshares - Admedus Name Change

Admedus has changed its name to Anteris Technologies

31st May 2020

Company Name Change

Change of company name from Admedus to Anteris Technologies

26th May 2020

Admedus 2020 AGM

Admedus 2020 AGM Video

14th May 2020

CEO Wayne Paterson is interviewed by Proactive Investors

CEO Wayne Paterson is interviewed by proactive investors to provide an update on Admedus in light of COVID-19

6th Apr 2020

First patient implanted with DurAVR™

Admedus implants first patient with their 3D single piece aortic valve

31st Mar 2020

Investor Q&A with Dr. Paul Sorajja & our CEO

Dr. Paul Sorajja shares his view on Admedus' TAVR

30th Mar 2020

Admedus is proud to announce the successful implantation of its ADAPT® treated single piece 3D aortic valve.

Admedus Limited announces the first implantation of its ADAPT® treated 3D single piece aortic valve in a patient with aortic stenosis.

29th Mar 2020

Credit Suisse Equity Research – US Medical Supplies & Devices

Week of Pre-Releases and Meetings Point to Solid Fundamentals and Healthy Innovation See the report here

1st Feb 2020

First-In-Human SAVR Trial Begins Q1 2020

ANNOUNCEMENT First-In-Human SAVR Trial Begins Q1 2020. Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals.

23rd Jan 2020